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Despite improvements in surgical techniques and com-
bined chemotherapies, the 5-year survival rate for all
stages of non-small cell lung cancer (NSCLC) is only
18%. Understanding the function of tumor infiltrating
lymphocytes (TILs) in NSCLC patient tumors will contri-
bute to the development of rationally designed treat-
ments and improved statistics. B cells in tumors (TIL-Bs)
are detected in non-small cell lung cancer (NSCLC) and
their frequency correlates with improved survival, how-
ever, the functional mechanism of TIL-Bs in solid tumors
is not well understood. We hypothesize that TIL-Bs help
generate potent, long-term immune responses against
cancer by presenting tumor antigens to CD4 tumor infil-
trating lymphocytes (TILs) in primary human lung
tumors.
Using un-manipulated, primary human B cells from
fresh tumor, tumor-adjacent, and normal (cancer-free)
lung tissue per the protocol described in Figure 1, we
observed that the total number of B cells at the site of
the tumor versus the tumor-adjacent tissue was
increased compared to other immune subsets (Figure 2).
Further, in analyzing B cell markers of activation and
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exhaustion, we observed a spectrum of activation of
TIL-Bs (Figure 2). Finally, we demonstrated that TIL-Bs
present autologous tumor antigens (particularly the can-
cer-testis antigen XAGE-1b) to CD4 TILs in a subset of
NSCLC patients; if the TIL-Bs were activated (CD69
+CD27+CD21+) they polarized the CD4 TILs to
T helper (anti-tumor) CD4 T cells and if the TIL-Bs
were exhausted (CD69-CD27-CD21-CD95+) they polar-
ized the CD4 TILs to T regulatory cells (pro-tumor)
(Figure 3 and Figure 4). These data suggest that TIL-Bs
polarize the phenotype and function of CD4 TILs in
NSCLC patient tumors.
In conclusion, TIL-Bs can have dual function in
NSCLC patient tumors, and determining if the TIL-Bs
are activated or exhausted will allow appropriate stimu-
lation of the anti-tumor function of TIL-Bs in NSCLC
patients. Ultimately, results from this study will help
predict how to target TIL-B functions in future TIL-B-
specific immunotherapies or in combination with cur-
rent immunotherapies for NSCLC patients like blockade
of the inhibitory receptor, PD-1.
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